Solution coating of braided absorbable multifilament suture with PURASORB PDLG 5010 begins with vacuum drying at 35–40°C under ≤1 mbar for 12–18 h to reduce residual moisture below 0.05% w/w. Anhydrous ethyl acetate is charged into a jacketed glass reactor maintained at 25°C, and the copolymer is added under dry nitrogen to a solids concentration of 6.0% w/w. The solution is stirred with an overhead PTFE anchor at 200–300 rpm for 6–8 h, then filtered through a 0.22 μm hydrophobic PTFE membrane. A braided polyglactin 910 suture substrate is passed through the coating bath at 8–12 m/min, metered by an air-knife die at 0.2–0.4 bar, and dried in a forced-air tunnel at 55–65°C with a dew point no higher than -20°C. The target dry coating add-on is 1.5–2.5% w/w, producing a film thickness of 5–15 μm. This coating reduces tissue drag and limits strand-to-strand abrasion during knot seating. The finished suture is subjected to ethylene oxide sterilization and tested for sterility to USP <71>, for cytotoxicity to ISO 10993-5:2009, and for residual ethylene oxide to ISO 10993-7:2008. Knot-pull tensile strength and needle-attachment force are evaluated under the appropriate USP monograph for the braided base fibre. Published degradation data for this coating configuration on braided suture are limited, so batch-specific molecular weight retention is verified by size-exclusion chromatography after accelerated ageing at 40°C and 75% relative humidity.

What Limits the Injection Moulding Window for a 50:50 PLGA Interference Screw?

Before melt processing, pellets are vacuum dried at 40°C to a residual moisture content of ≤0.02% w/w because residual water acts as a chain-scission nucleophile at the ester linkages. A 25 mm general-purpose screw with an L/D 24:1 and compression ratio of 2.5:1 is used. Barrel settings from feed to nozzle are commonly 150°C, 165°C, 175°C, and 170°C. The mould is chilled to 10–20°C because the amorphous copolymer has no crystalline reinforcement and would remain soft if ejected above its glass transition of approximately 45–55°C. Injection speed is held at 40–80 mm/s, hold pressure at 400–800 bar for 2–4 s, and screw cushion at 3–5 mm. Total melt residence time is kept below 8 min to limit molecular weight loss above 180°C. A cold sprue with a 1.0–1.5 mm round gate is preferred to reduce shear heating. After moulding, parts are annealed in nitrogen at 50°C for 4 h and packaged in moisture-barrier pouches. Testing of the finished interference screw includes dimensional recovery after accelerated ageing, inherent viscosity measurement by ISO 1628-1:2021, and mechanical evaluation under ASTM F2502-17. Biocompatibility endpoints include ISO 10993-5:2009, ISO 10993-10:2021, and ISO 10993-6:2016. Published data for this exact grade in small orthopaedic fixation devices are limited; the processing window must therefore be revalidated on each mould because small changes in residual moisture shift melt viscosity and final molecular weight.

Resorbable embolization microspheres in the 100–300 μm size range are produced from PURASORB PDLG 5010 by oil-in-water solvent evaporation. The dispersed phase is prepared by dissolving the copolymer in dichloromethane at 12% w/w and filtering through a 0.45 μm PTFE capsule. The continuous phase is 0.5% w/w polyvinyl alcohol in water for injection at 4°C. The phases are combined in a 2 L jacketed reactor at a water-to-oil ratio of 10:1, using a pitched-blade stirrer at 500–700 rpm. The dispersion is maintained at 4°C for 2 h and then warmed to 25°C for 4 h to evaporate the solvent. Microspheres are collected on 100 μm and 300 μm sieves, washed with water for injection to remove residual polyvinyl alcohol, and lyophilized at -40°C and 0.1 mbar for 48 h. Residual dichloromethane is controlled by gas chromatography to the limit specified for the finished device. Endotoxin testing follows USP <85>, and sterility is validated to USP <71>. Gamma irradiation at 25 kGy is used for terminal sterilization; because irradiation induces chain scission, molecular weight after irradiation is confirmed by size-exclusion chromatography. The acid-terminated chain ends of this copolymer produce faster initial hydration and more uniform core degradation than ester-capped PLGA of equivalent inherent viscosity. If active pharmaceutical ingredient loading is introduced, the regulatory classification shifts to a drug-device combination product and additional pharmacopoeial controls apply; otherwise the embolization microsphere is regulated as a medical device.

Electrospun Tubular Scaffolds Demand a Two-Zone Humidity-Defined Spinning Envelope

For vascular and tracheal tissue-engineering scaffolds, PURASORB PDLG 5010 is dissolved in 1,1,1,3,3,3-hexafluoroisopropanol at 14% w/v or in a 75:25 dichloromethane:dimethylformamide mixture at 18% w/v. The solution is loaded into a 5 mL glass syringe and delivered through a 0.6 mm blunt needle at 0.8–1.5 mL/h. A high-voltage supply applies 18–22 kV to the needle, and a grounded rotating drum collector at 500 rpm is positioned 15–18 cm from the tip. Spinning is controlled in two humidity zones: the first 5 cm after the needle is maintained at 25–30% relative humidity to stabilise jet formation, while the collector chamber is held at 45–50% relative humidity to facilitate residual solvent removal. Fibre diameter is typically 0.8–2.5 μm, and pore size is characterised by mercury intrusion porosimetry or micro-computed tomography at 5 μm resolution. After spinning, the scaffold is vacuum dried at 30°C for 48 h to reduce residual solvent below the device-specific limit. The terminal product is an electrospun tubular conduit or patch for soft-tissue repair. Cytotoxicity is evaluated under ISO 10993-5:2009, and the device-specific degradation profile is measured by mass loss and molecular weight retention in phosphate-buffered saline at 37°C. Published data for dynamic humidity-gradient electrospinning of this specific PDLG grade remain limited; each lot therefore requires re-qualification of jet stability and fibrous morphology.

When PLGA 5010 Is Melt-Compounded with β-Tricalcium Phosphate for Craniofacial Meshes

Composite devices intended for craniofacial fixation require a dispersant protocol because β-tricalcium phosphate particles below 10 μm form agglomerates at loadings above 20% w/w. The β-tricalcium phosphate is first dried at 120°C for 4 h, while PURASORB PDLG 5010 is vacuum dried at 40°C to ≤0.02% w/w residual moisture. A micro twin-screw compounder with barrel temperature 150–160°C and screw speed 60 rpm is used to disperse 30% w/w β-tricalcium phosphate into the PLGA matrix under nitrogen purge. Residence time is held below 5 min to avoid chain scission. The extruded strand is pelletized and compression moulded at 150°C under 10 MPa for 3–5 min into sheets of 0.5–1.2 mm thickness, which are subsequently cut into mesh forms. This manufacturing route produces a resorbable craniofacial mesh with improved osteoconductive surface properties compared with unfilled PLGA. Material evaluation includes ASTM F2902-16 for absorbable polymeric implants, ISO 10993-5:2009 for cytotoxicity, and ISO 10993-6:2016 for local implantation effects. The composite is not intended for load-bearing long-bone fixation because the 50:50 PLGA matrix loses strength more rapidly than slower-degrading poly(L-lactide) devices. Published data for this specific filler loading with PDLG 5010 are limited, and dispersion uniformity must be confirmed by scanning electron microscopy on each compression-moulded sheet.

To delay corrosion onset on magnesium alloy bioresorbable scaffolds, ultrasonic spray deposition is used to apply a 2–5 μm barrier layer of PURASORB PDLG 5010. The substrate is cleaned with anhydrous ethanol and dried with dry nitrogen; plasma treatment is omitted where the magnesium oxide layer must remain intact. The coating solution is prepared at 0.5% w/w solids in anhydrous ethyl acetate and filtered through a 0.2 μm PTFE membrane. An ultrasonic nozzle operating at 60 kHz delivers solution at 0.1–0.3 mL/min to the rotating substrate at 1–2 rpm, with substrate temperature held at 35°C. The coating is built in multiple passes with interpass drying of 20 s. Thickness is measured by spectral reflectance or scanning electron microscopy, and coating adhesion is assessed by tape test after soaking in phosphate-buffered saline at 37°C for 24 h. The coated device is evaluated for in vitro corrosion behaviour by ASTM F2129-19, for sterility by USP <71>, and for endotoxin by USP <85>. The terminal product is a temporary vascular scaffold, not a permanent implant. Because PLGA absorbs water and undergoes hydrolytic degradation, the barrier layer is intended to reduce the initial corrosion burst rather than provide long-term isolation. Residual ethyl acetate is controlled to the device specification after vacuum drying at 30°C for 24 h.

Solvent-Cast Guided Tissue Regeneration Membranes: Casting Speed, Pore Morphology, and Residual Solvent Limits

For periodontal guided tissue regeneration, PURASORB PDLG 5010 is dissolved in dimethyl carbonate or ethyl acetate at 8–12% w/w. The solution is cast onto a PTFE-coated glass plate using a doctor blade with a gap of 300–600 μm. Drying is conducted at 25°C and <30% relative humidity for 24 h, followed by vacuum drying at 30°C for 48 h to reduce residual solvent to the device-specific limit. The resulting membrane has a thickness of 50–150 μm and serves as a barrier to epithelial downgrowth while permitting nutrient diffusion. Mechanical properties are measured by ASTM D882-18 for thin plastic sheeting, and porosity is determined by mercury intrusion porosimetry. The acid-terminated PLGA matrix is expected to lose mass after the 4–6 week barrier period required for guided tissue regeneration, but published in vivo degradation data for this exact grade in periodontal membranes are limited. Cytotoxicity is tested by ISO 10993-5:2009, and sterility is confirmed by USP <71>. Packaging under nitrogen and use of a desiccant are required where ambient relative humidity exceeds 60%, because the copolymer absorbs sufficient moisture to initiate hydrolysis before implantation.